3Bryce J, Boschi-Pinto C, Shibuya K, et al. WHO esti- mates of the causes of death in children [J]. Lancet, 2005, 365(9465): 1147-1152.
4Shoham Y, Dagan R, Givon-Lavi N, et al. Community- acquired pneumonia in children: quantifying the burden on patients and their families including decrease in quality of life [J]. Pediatrics, 2005, 115(5): 1213-1219.
5Ngeow YF, Suwanjutha S, Chantarojinasriri T, et al. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia [J]. Int J In- fect Dis, 2005, 9(3): 144-153.
6Waites KB, Talkington DF. Myeoplasma pueumoniae and its role as a human pathogen [J]. Clin Microbiol Rev, 2004, 17(4): 697-728.
7YounYS, 1 LeeKY, HwangJY, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia [J]. BMC Pediatr, 2010, 10: 48.
8Waites KB, Balish MF, Atkinson TP. New insight into the pathogenesis and detection of Mycoplasma pneumoniae infections [J]. Future Microbiol, 2008, 3(6): 635-648.
9Tagliabue C, Salvatore CM, Techasaensiri C, et al. The impact of steroids given with macrolide therapy on experi- mental Mycoplasma pneumoniae respiratory infection [J]. J Infect Dis, 2008, 198(8): 1180-1188.
10Werdan K, Pial G. Supplemental immunoglobulins in sepsis: a critical appraisal [J]. Clin Exp Immunol, 1996, 104(suppl.1): 83-90.
